Browsing: LisoCel

Diagnosis

Real-World CAR-T Comparisons: Axi-cel vs Liso-cel in 2L LBCL

By NewsCancerMarch 18, 20260

Team Roswell presents ABC Consortium real-world data from 15 US centers comparing second-line outcomes with axi-cel, liso-cel, and a third…

Diagnosis

Comparing Outcomes in AYA Vs Older Populations Receiving Liso-cel for LBCL

By NewsCancerFebruary 26, 20260

In a conversation with CancerNetwork®, Irtiza Sheikh, DO, an assistant professor in the Department of Pediatrics – Patient Care, Stem…

Treatments

Examining CAR-T Outcomes in 2L LBCL Treatment (Axi-cel & Liso-cel, DESCAR-T Registry)

By NewsCancerFebruary 21, 20260

Panelists analyze comparative real-world data from the French DESCAR-T registry evaluating axicabtageneciloleucel and lisocabtagenemaraleucel in second-line relapsed/refractory LBCL. Faculty consider…

Survivors

Considerations For Future Liso-Cel Research Across Clinical Characteristics

By NewsCancerFebruary 16, 20260

Despite there not being significant differences in efficacy with lisocabtagene maraleucel (liso-cel; Breyanzi) across real-world and clinical trial settings, more…

What's Hot

CD39/PD-L1 Inhibition May Improve pCR Rate in Resectable NSCLC

Cilta-Cel Produces Early Responses in Smoldering Multiple Myeloma

Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure

Browsing: LisoCel

Real-World CAR-T Comparisons: Axi-cel vs Liso-cel in 2L LBCL

Comparing Outcomes in AYA Vs Older Populations Receiving Liso-cel for LBCL

Examining CAR-T Outcomes in 2L LBCL Treatment (Axi-cel & Liso-cel, DESCAR-T Registry)

Considerations For Future Liso-Cel Research Across Clinical Characteristics

CD39/PD-L1 Inhibition May Improve pCR Rate in Resectable NSCLC

Cilta-Cel Produces Early Responses in Smoldering Multiple Myeloma

Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure

Ramucirumab Regimen Yields Noninferior OS Vs SOC in Stage IV NSCLC

CD39/PD-L1 Inhibition May Improve pCR Rate in Resectable NSCLC

Cilta-Cel Produces Early Responses in Smoldering Multiple Myeloma

Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure

Ramucirumab Regimen Yields Noninferior OS Vs SOC in Stage IV NSCLC

Latest Post

CD39/PD-L1 Inhibition May Improve pCR Rate in Resectable NSCLC

Cilta-Cel Produces Early Responses in Smoldering Multiple Myeloma

Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure

Subscribe to Updates

What's Hot

Browsing: LisoCel